FDA Orders Vision-Loss Warning on Ozempic, Zepbound and Other GLP-1 Drugs
The FDA ordered Novo Nordisk, Eli Lilly and AstraZeneca to warn of possible vision loss from NAION on all GLP-1 drug labels, matching Europe's earlier move.
Topic
Zepbound
Topic
Zepbound
Hims & Hers Stock Jumps 4.7% on Eli Lilly GLP-1 Deal
Hims & Hers will sell Eli Lilly's Zepbound and Foundayo directly, dropping compounding. Shares rose 4.7% Friday but remain down 2…
Eli Lilly Raises 2026 Revenue Outlook to $91–92 Billion
Lilly raised 2026 revenue guidance to $91–92 billion after Q3 EPS of $7.48 beat estimates of $6.26, as Mounjaro sales jumped 65%…
Lilly Claims 61% of US GLP-1 Market as Novo Bets $23B Pipeline
Lilly holds 61% of the U.S. GLP-1 market and is gaining in pills and Medicare. Novo counters with a $23 billion pipeline bet, but…
Lilly Claims 70% of 700,000 New Medicare GLP-1 Seniors
Eli Lilly CEO Dave Ricks says 700,000 seniors started GLP-1s since July's Medicare coverage launch — and 70% of them are on Lilly…